Evidence map›Paper›PMID 40878389›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2026

An Ultrapotent, Ultraeconomical, Antifreeze Polypeptide.

Thomas J McPartlon, Charles T Osborne, Ke Wang, Rachel E Detwiler, Konrad Meister, Jessica R Kramer

Abstract read
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. An Ultrapotent, Ultraeconomical, Antifreeze Polypeptide.Advanced materials (Deerfield Beach, Fla.) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Thomas J McPartlonDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, 84112, USA.
Charles T OsborneDepartment of Biomedical Engineering, University of Utah, Salt Lake City, UT, 84112, USA.
Ke WangDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, 84112, USA.
Rachel E DetwilerDepartment of Biomedical Engineering, University of Utah, Salt Lake City, UT, 84112, USA.
Konrad MeisterDepartment of Chemistry and Biochemistry, Boise State University, Boise, ID, 83725, USA.
Jessica R KramerDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, 84112, USA.ORCID https://orcid.org/0000-0002-4268-0126

Funding

National Science Foundation DMR-2300012
6 · The paper itself

Abstract

The growth of large ice crystals during freeze and thaw events is a challenge in diverse settings from transportation and agriculture to foods and biomedicine. Design, synthesis, and evaluation of antifreeze polypeptides that inhibit ice crystal growth at µg concentrations are reported herein. The polypeptides, composed of Ala and Glu, are prepared using economical methodology, are stable after thermal events, are biodegradable, and are nontoxic to human cells. Mirror-image polypeptides have resisted degradation and are suitable for applications with a longevity criterion. Their α-helical conformation plays a role in antifreeze activity, but chirality does not. In proof-of-concept experiments, the antifreeze polypeptides could prevent damage to model protein therapeutics during repeated freeze-thaw cycles and could be applied to prevent large ice crystals in a frozen food product. These simple, economical Ala/Glu polypeptides are promising materials for diverse antifreeze applications, particularly in biological settings.

Indexed as

Antifreeze ProteinsPeptidesFreezingHumansIceAntifreeze ProteinsIcePeptidesantifreezecryopreservationcryoprotectantIRIN‐carboxyanhydridepolypeptide

Identifiers

PMID40878389
PMCPMC12810662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.